Antibe Therapeutics Inc.
ATBPF
$0.2156
$0.025613.47%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -2.35% | -16.39% | 41.62% | 7.08% | -11.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.64% | -18.53% | 2.96% | -38.50% | -17.30% |
| Operating Income | 1.64% | 18.53% | -2.96% | 38.50% | 17.30% |
| Income Before Tax | 0.04% | 22.06% | 1.84% | 42.68% | 25.19% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 0.04% | 22.06% | 1.84% | 42.68% | 25.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -721.83% | -127.86% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.61% | 19.90% | 0.60% | 36.59% | 17.36% |
| EBIT | 1.64% | 18.53% | -2.96% | 38.50% | 17.30% |
| EBITDA | -- | -- | -- | 38.65% | 17.06% |
| EPS Basic | 3.29% | 20.69% | 1.56% | 37.23% | 18.06% |
| Normalized Basic EPS | 0.54% | 22.82% | 2.85% | 43.31% | 25.85% |
| EPS Diluted | 3.29% | 20.69% | 1.56% | 37.23% | 18.06% |
| Normalized Diluted EPS | 0.54% | 22.82% | 2.85% | 43.31% | 25.85% |
| Average Basic Shares Outstanding | 0.63% | 0.97% | 0.99% | 1.05% | 0.96% |
| Average Diluted Shares Outstanding | 0.63% | 0.97% | 0.99% | 1.05% | 0.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
